InsidersTradesSigma
Hansa Biopharma AB: management transactions · Finland · FIN-FSA
FI:hansa-biopharma-abSE0002148817FI·FIN-FSAMcap 2.9Bn€Healthcare
Browse the full management transaction log of Hansa Biopharma AB, a listed equity based in Finland. Shares are listed on FI FI, under the oversight of FIN-FSA. Operating in the Healthcare sector, Hansa Biopharma AB has logged 5 insider filings. Market capitalisation: €2.9bn. The latest transaction was filed on 11 March 2026 (Purchase). Among the most active insiders: RENÉE AGUIAR LUCANDER. All data is accessible without an account.
5
Insider Decl.
0
Thresholds
€2m
4 ops.
Buy Volume
€19,037
1 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
28.84 €
Analyst consensus
7 analystsStrong buy
35.00 €Target 75.00 €(+160%)103.00 €
Income statement
Revenue222.3 M€
Gross profit138.7 M€62% margin
Net income−534.1 M€-240.3% margin
Valuation
PER (forward)-7.2x
Beta1.50
Balance sheet & cash
Market cap2.88 Bn€
Total debt938.7 M€
Free Cash Flow−549.2 M€
Profitability & ownership
ROA-38.2%
% insiders9.8%
% institutions47.5%
Last declaration on 11 March 2026
Declarations5 total
Executives●Purchase19FIN-FSA
€4,6891,688 shares@ €2.77810.0002% mcap100.0% of flow
Aktie
FI:A003W932-1·
Ideal exit: 6 Dec 2026 (T+270)
Executives●Purchase39FIN-FSA
€2m1,652,500 shares@ €0.9740.056% mcap92.9% of flow
Teckningsoption
FI:A003R120-1·
Ideal exit: 23 Apr 2026 (T+270)
Executives●Purchase27FIN-FSA
€122,93450,000 shares@ €2.45870.0043% mcap7.1% of flow
Aktie
FI:A003R122-1·
Ideal exit: 24 Apr 2026 (T+270)
Executives●Sale19FIN-FSA
€19,0378,056 shares@ €2.36310.0007% mcap100.0% of flow
Aktie
FI:A003R005-1·
Executives●Purchase15FIN-FSA
015,050 shares0
Aktie
FI:A003R004-1·
Ideal exit: 18 Apr 2026 (T+270)
5 of 5 declarations